Envestnet Asset Management Inc. Purchases 13,248 Shares of Agilent Technologies, Inc. (NYSE:A)

Envestnet Asset Management Inc. grew its position in shares of Agilent Technologies, Inc. (NYSE:A) by 1.7% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 771,162 shares of the medical research company’s stock after buying an additional 13,248 shares during the quarter. Envestnet Asset Management Inc. owned 0.26% of Agilent Technologies worth $99,966,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of A. Vanguard Group Inc. grew its position in Agilent Technologies by 18.2% during the first quarter. Vanguard Group Inc. now owns 29,884,345 shares of the medical research company’s stock valued at $4,348,471,000 after buying an additional 4,605,228 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Agilent Technologies by 13.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,542,054 shares of the medical research company’s stock worth $1,242,956,000 after purchasing an additional 1,042,926 shares during the last quarter. Van ECK Associates Corp raised its holdings in shares of Agilent Technologies by 0.7% in the 2nd quarter. Van ECK Associates Corp now owns 2,793,189 shares of the medical research company’s stock worth $362,081,000 after purchasing an additional 18,205 shares during the period. Nordea Investment Management AB lifted its stake in Agilent Technologies by 4.4% in the first quarter. Nordea Investment Management AB now owns 2,783,238 shares of the medical research company’s stock valued at $406,715,000 after purchasing an additional 116,822 shares during the last quarter. Finally, Impax Asset Management Group plc grew its holdings in Agilent Technologies by 8.5% during the second quarter. Impax Asset Management Group plc now owns 2,464,382 shares of the medical research company’s stock valued at $319,458,000 after purchasing an additional 193,012 shares during the period. Hedge funds and other institutional investors own 87.42% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Robert W. Baird dropped their price target on Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating on the stock in a research report on Thursday, May 30th. TD Cowen increased their target price on shares of Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Wells Fargo & Company assumed coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $157.00 price target on the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $135.00 price objective (down from $152.00) on shares of Agilent Technologies in a report on Monday, June 3rd. Finally, Citigroup lifted their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $141.60.

Agilent Technologies Stock Performance

Shares of A opened at $138.35 on Wednesday. Agilent Technologies, Inc. has a 12-month low of $96.80 and a 12-month high of $155.35. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. The company has a market cap of $40.37 billion, a PE ratio of 32.71, a price-to-earnings-growth ratio of 6.43 and a beta of 1.05. The stock has a 50-day moving average price of $137.26 and a 200-day moving average price of $139.25.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.06. The business had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. Agilent Technologies’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.43 earnings per share. As a group, equities analysts forecast that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $140.00, for a total transaction of $274,120.00. Following the sale, the chief executive officer now owns 26,076 shares in the company, valued at $3,650,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is owned by company insiders.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.